Open Orphan (LSE:ORPH) advanced 3% to 23.7p on Monday morning after revealing a contract renewal expected to deliver “significant revenue” over the next 12 months. The specialist pharma services...
Venn Life Sciences
Open Orphan has a great start to 2021 with key 12-month contract renewal
Open Orphan PLC (LSE: ORPH) has recently extended a contract with a top-three global pharma company. Its Venn Life Services subsidiary, operating out of Breda, Netherlands, will provide chemistry,...
Open Orphan wins vaccine contract extension and announces toxicology study completion
Open Orphan (LSE: ORPH) subsidiary Venn Life Sciences has extended a consulting contract with a global pharma firm to support two vaccine development programmes. Venn’s Breda office in the...
Open Orphan continues to convert deal pipeline with key Venn contracts
Open Orphan’s (LSE:ORPH) strong run continued on Monday morning with the news that it has won two new contracts bolstering its presence in the global fight against coronavirus. The pharmaceutical...
Open Orphan strengthens board with Elaine Sullivan hire
Open Orphan (LSE:ORPH) Tuesday saw pharmaceutical services player Open Orphan (LSE:ORPH) announce the appointment of Elaine Sullivan as a non-executive director to its board. Sullivan is business...
Open Orphan hits record highs after winning £4.3m vaccine contract
Open Orphan (LSE:ORPH) shot up to record highs on Monday morning after unveiling a £4.3 million contract with a global top ten vaccine company. Shares in the pharmaceutical services player have been...
Round-up: Busy week for Open Orphan as it pushes forward Covid and oncology arms (ORPH)
Open Orphan (LSE:ORPH) has confirmed that it is in advanced negotiations with the UK government for a coronavirus challenge study. In a Thursday update in response to a spike in its share price, the...